Nuclear-localized metabolic enzymes: emerging key players in tumor epigenetic regulation
- PMID: 40434518
- DOI: 10.1007/s11010-025-05316-w
Nuclear-localized metabolic enzymes: emerging key players in tumor epigenetic regulation
Abstract
Advancements in tumor research have highlighted the potential of epigenetic therapies as a targeted approach to cancer treatment. However, the application of these therapies has faced challenges due to the issue of substrate availability since the discovery of epigenetic modifications. Interestingly, metabolic changes are closely associated with epigenetic changes, and notably, certain metabolic enzymes exhibit nuclear localization within epigenetically active cellular contexts. This suggests that nuclear localization of metabolic enzymes may provide a mechanistic foundation for addressing substrate availability issues in epigenetic regulation. To date, there has been limited progress in synthesizing this information systematically. In this study, we provide an overview of the interplay between metabolic enzymes and epigenetic mechanisms, highlighting their critical roles. Subsequently, we summarize recent advances regarding the nuclear localization of metabolic enzymes, shedding light on their emerging roles in epigenetic regulation and oncogenesis.
Keywords: DNA demethylation; Epigenetic modifications; Histone modifications; Lactylation; Nuclear localization of metabolic enzymes.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethical approval: This study did not involve the participation of human or animal subjects, and, therefore, was exempt from formal assessment by the ethics committee for clinical research of our center. Consent for publication: Not applicable.
References
-
- Allis CD, Jenuwein T (2016) The molecular hallmarks of epigenetic control. Nat Rev Genet 17(8):487–500. https://doi.org/10.1038/nrg.2016.59 - DOI - PubMed
-
- Mashtalir N, Suzuki H, Farrell DP, Sankar A, Luo J, Filipovski M, D’Avino AR, St Pierre R, Valencia AM, Onikubo T, Roeder RG, Han Y, He Y, Ranish JA, DiMaio F, Walz T, Kadoch C (2020) A structural model of the endogenous human BAF complex informs disease mechanisms. Cell 183(3):802-817.e24. https://doi.org/10.1016/j.cell.2020.09.051 - DOI - PubMed - PMC
-
- Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059 - DOI - PubMed
-
- Baylin SB, Jones PA (2016) Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 8(9):a019505. https://doi.org/10.1101/cshperspect.a019505 - DOI - PubMed - PMC
-
- Xu X, Peng Q, Jiang X, Tan S, Yang Y, Yang W, Han Y, Chen Y, Oyang L, Lin J, Xia L, Peng M, Wu N, Tang Y, Li J, Liao Q, Zhou Y (2023) Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp Mol Med 55(7):1357–1370. https://doi.org/10.1038/s12276-023-01020-1 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical